SENTINEL NODE BIOPSY BY TWO KINDS OF BLUE DYES IN PATIENTS WITH BREAST CANCER

Ｓｅｎｔｉｎｅｌｎｏｄｅｂｉｏｐｓｙ (ＳＮＢ)ｔｅｃｈｎｉｑｕｅｉｓｌｉｋｅｌｙｔｏｒａｄｉｃａｌｌｙｍｏｄｉｆｙｔｈｅｓｕｒｇｉｃａｌｍａｎａｇｅｍｅｎｔｏｆｔｈｅａｘｉｌｌａｉｎｂｒｅａｓｔｃａｎｃｅｒｐａｔｉｅｎｔｓ1 6] .ＴｈｅｐｏｓｓｉｂｉｌｉｔｙｏｆＳＮＢｍａｙｅｎａｂｌｅｓｕｒｇｅｏｎｔｏｒｅｆｒａｉｎｆｒｏｍａｘｉｌｌａｒｙｌｙｍｐｈｎｏｄｅｄｉｓｓｅｃｔｉｏｎ (ＡＬＮＤ )ｉｎｃｌｉｎｉｃａｌｌｙｎｏｄｅｎｅｇａｔｉｖｅｂｒｅａｓｔｃａｎｃｅｒ ｐａｔｉｅｎｔｓｗｉｔｈｈｉｓｔｏｌ…

SENTINEL NODE BIOPSY BY TWO KINDS OF BLUE DYES IN PATIENTS WITH BREAST CANCER

Objective To evaluate the identification successful rate of sentinel lymph node (SLN) with breast cancer and the accuracy to predict axillary lymph node status in different vital blue dyes.Methods 94 patients with breast cancer were recruited for the study between Oct. 1999 and Apr. 2001, of whom 32 and 62, respectively, were injected 0.028mmol*L-1 Methylene blue and 0.018mmol*L-1 Patent blue violet in breast parenchyma surrounding the primary tumor to identify SLN.All 94 patients underwent the axillary lymph node dissection.Results For Methylene blue group and Patent blue violet group, SLN identification successful rates were 65.6% (21/32) and 88.7% (55/62) (P=0.012) and accuracy rate to predict axillary lymph node status were 90.5% (19/21) and 98.2% (54/55) (P=0.183), respectively.Conclusion In identifying SLN,Patent blue violet is more ideal vital blue dye than Methylene blue, whereas the accuracy rate to predict axillary lymph node status had no significant difference.